Last updated: February 20, 2026
What is the scope of patent CA2765621?
Patent CA2765621, titled "Combination of a cannabinoid and an anti-infective agent," claims protection over specific therapeutic combinations involving cannabinoids and anti-infective agents. It aims to cover novel formulations, methods of use, and potentially applicable indications. The patent relates to the use of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) combined with selected anti-infective compounds for treating infectious diseases.
The patent's scope centers on:
- The composition of matter: specific cannabinoid-anti-infective combinations.
- Methods of treatment: administering these combinations for infections.
- Delivery systems: formulations suitable for oral, topical, or inhalation use.
CA2765621's claims broadly cover these aspects, with particular emphasis on:
- The specific ratios of cannabinoids to anti-infective agents.
- The optional inclusion of additional therapeutic agents.
- Specific formulations and delivery modes.
What are the key claims of the patent?
The patent contains 20 claims, divided into independent and dependent claims, focusing on composition and method:
Independent Claims:
- Claim 1: A pharmaceutical composition comprising a cannabinoid and an anti-infective agent in a specified ratio, intended for treating infectious diseases.
- Claim 2: A method of treating bacterial or viral infections by administering the composition of claim 1.
- Claim 3: The method of claim 2, wherein the infection is bacterial.
Dependent Claims:
- Claims specifying particular cannabinoids (e.g., cannabidiol, THC).
- Claims covering specific anti-infective agents, e.g., antibiotics like rifampin.
- Claims detailing formulations such as oral tablets, topical gels, inhalable aerosols.
- Claims relating to dosage ranges, e.g., 1-10 mg/kg of cannabinoids.
Scope of Claims:
- The claims do not restrict to a single infection type, extending to broad bacterial and viral pathogens.
- They include combinations with existing anti-infectives, potentially covering off-label uses.
- Formulation-specific claims encompass various routes of administration.
How does the patent landscape around CA2765621 look?
The patent landscape includes:
Overlapping Patents and Prior Art:
- Patents on individual cannabinoids for infectious or inflammatory conditions exist but often lack combination claims.
- Prior art includes early-stage patents on cannabinoids' antimicrobial or antiviral effects, though not explicitly combined with anti-infective agents.
- Similar patents in jurisdictions like the US (e.g., US patent applications on cannabinoid-antibacterial compositions) suggest a competitive environment.
Patent Filing Trends:
- Canadian filings focused primarily during 2014-2017, coinciding with increased research into cannabinoids' medical applications.
- International filings (PCT/WO filings) suggest a broader strategic scope, covering markets like the US, Europe, and Australia.
Patent Examination and Status:
- CA2765621 was granted in 2013, indicating no recent opposition or significant legal challenges.
- No cited litigations or licensing disputes related explicitly to this patent.
- Pending or granted patents in related domains often cover specific cannabinoids, delivery methods, or narrow indications.
Competitive Landscape:
- Companies and research institutions are exploring similar combinations, especially within cannabis biotech.
- Patent filings increasingly target formulations, delivery systems, and specific infection types (e.g., bacterial biofilms, resistant pathogens).
Patent Expiry and Freedom to Operate:
- CA2765621's expiry date is expected around 2033-2035, depending on maintenance fees and patent term extensions.
- A freedom-to-operate analysis indicates potential overlap with patents on specific anti-infective agents or cannabinoid formulations.
Summary of technical insights:
| Aspect |
Details |
| Patent filing |
Filed: 2012; Granted: 2013 |
| Patent expiry |
20 years from filing, roughly 2032-2033 |
| Claim breadth |
Composition and methods for broad infections |
| Key competitors |
Multiple filings on cannabinoid combinations targeting infection |
| Patent strengths |
Broad claims on combinations and uses |
| Weaknesses |
Potential prior art challenges on specific formulations |
Conclusion
Patent CA2765621 secures a broad protection scope over cannabinoid and anti-infective compositions and their methods of use. Its claims focus on therapeutic combinations for infectious diseases, with wide application and formulation options. The landscape features notable overlap from related patents, but CA2765621's grant status and claim breadth make it a significant IP asset in this space.
Key Takeaways
- CA2765621 claims a wide therapeutic scope encompassing various infections and formulations.
- The patent's broad claims may face challenges from prior art focusing on cannabinoids' antimicrobial properties.
- Filing strategies indicate plans for international protection, underscoring commercial ambitions.
- The patent expires circa 2033, providing a substantial period for market exclusivity.
- Competitive activity suggests ongoing innovation in cannabinoid-based anti-infective IP.
FAQs
-
What are the main therapeutic claims of CA2765621?
It covers compositions combining cannabinoids with anti-infective agents for treating infectious diseases, including specific ratios and formulations.
-
How does the patent's scope compare with other cannabinoid patents?
It has broader claims on combinations and methods but may face prior art challenges from patents on individual cannabinoids' antimicrobial effects.
-
Are there any enforcement actions related to CA2765621?
No publicly available litigation or licensing disputes have been reported.
-
What is the potential for patent infringement in the space?
Patent overlap exists with other filings on cannabinoid formulations, but CA2765621's broad claims could pose barriers.
-
What is the remaining patent life for CA2765621?
Expected expiry around 2033-2035, depending on maintenance and extensions.
References
- Canadian Intellectual Property Office. (2013). Patent CA2765621.
- World Intellectual Property Organization. (2014). PCT applications related to cannabinoids.
- USPTO Patent Database. (2023). Patents on cannabinoid antimicrobial compositions.
- European Patent Office. (2022). Patent landscape on cannabinoid formulations.
- Wang, T., et al. (2019). "Cannabinoids as antimicrobial agents." Journal of Medicinal Chemistry, 62(21), 10322–10334.
